News

Nasdaq1y
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting - Nasdaq
BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of ...
New York Post3mon
Robo cops, AI schooling, food from 3-D printers and post-work future are anticipated for Praxians
Dryden Brown said that Praxis “is going to be something you’ve never seen before.” Courtesy of Praxis. Although Brown’s ideas may sound far-fetched and idealistic to some, he’s managed ...
Nasdaq5mon
Praxis Precision Medicines Highlights Late-Stage Clinical Trial Advancements and 2025 Milestones - Nasdaq
Praxis has earned an option exercise fee and is eligible to receive future success-based development and commercialization milestone payments, for a total of up to approximately $100 million, in ...
Business Insider1y
Praxis Precision Medicines, Inc. Announces Pricing of $150.0 Million Public Offering - Markets Insider
BOSTON, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies ...
The North Bay Business Journal11y
Praxis eyes more multifamily, future of 'flipping'
SANTA ROSA -- When Santa Rosa's Praxis Capital launched as a vehicle for real estate investment in 2009, the firm was inundated with opportunities to buy, refurbish and resell deeply discounted ...
Mena FN1y
Praxis Precision Medicines To Present On Ulixacaltamide At The American Academy Of Neurology 2024 Annual Meeting - MENAFN.COM
Innovative design of ongoing Phase 3 clinical program expected to set precedent for future clinical trials in essential tremorBOSTON, April ...
Yahoo Finance2y
Praxis Precision Medicines to Present at the American Academy of Neurology 2023 Annual Meeting - Yahoo Finance
BOSTON, April 19, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of ...
WTNH1y
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting - WTNH.com
BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of ...
Yahoo Finance1y
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting - Yahoo Finance
Innovative design of ongoing Phase 3 clinical program expected to set precedent for future clinical trials in essential tremorBOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines ...
FOX8 Cleveland1y
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting - Fox 8 Cleveland WJW
BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of ...
KRQE Blogs1y
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting - KRQE NEWS 13
BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of ...
Yahoo Finance1y
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting - Yahoo Finance
Innovative design of ongoing Phase 3 clinical program expected to set precedent for future clinical trials in essential tremorBOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc ...